Penserra Capital Management LLC Has $151,000 Holdings in Gilead Sciences, Inc. $GILD

Penserra Capital Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1,241.2% in the second quarter, HoldingsChannel reports. The firm owned 1,368 shares of the biopharmaceutical company’s stock after acquiring an additional 1,266 shares during the period. Penserra Capital Management LLC’s holdings in Gilead Sciences were worth $151,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC acquired a new position in shares of Gilead Sciences during the first quarter worth approximately $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $238,083,000. Los Angeles Capital Management LLC raised its position in Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after buying an additional 1,942,433 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 1.5%

Shares of NASDAQ:GILD opened at $125.20 on Friday. The firm has a market cap of $155.33 billion, a price-to-earnings ratio of 24.94, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $127.68. The company’s fifty day simple moving average is $117.24 and its 200 day simple moving average is $112.64. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter in the prior year, the company earned $2.02 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider owned 110,193 shares of the company’s stock, valued at $13,011,589.44. The trade was a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 94,646 shares of company stock worth $11,311,286. 0.27% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on GILD shares. Daiwa Capital Markets lifted their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Argus raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Finally, Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $129.13.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.